In the DRCR Protocol T comparison of ranibizumab, bevacizumab and aflibercept for centre-involving diabetic macular oedema, which agent produced the greatest visual gain at 1 year among eyes with baseline acuity of 20/50 or worse?
- A Aflibercept ✓
- B Ranibizumab
- C Bevacizumab
- D All three agents gave equivalent results
Correct answer: A. Aflibercept
Explanation
Protocol T found that at 1 year all three agents were similar in eyes starting at 20/40 or better, but in the subgroup with baseline acuity of 20/50 or worse aflibercept was significantly superior, with mean gains around 18 letters versus roughly 13 for ranibizumab and 11 for bevacizumab. The equivalence result in better-seeing eyes makes option D attractive but incorrect, since equivalence held only for the milder subgroup.
Reference: Ryan's Retina, 6th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.